GW Pharmaceuticals’ cannabis-derived epilepsy drug wins European approval
The European Commission approved GW Pharma's Epidyolex as a treatment for seizures in two rare and severe forms of epilepsy. The drug won FDA approval last year.
The European Commission approved GW Pharma's Epidyolex as a treatment for seizures in two rare and severe forms of epilepsy. The drug won FDA approval last year.
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The FDA approved the cannabis-based drug for treating seizures in two severe forms of epilepsy.